-
- Shunichi Nishima, Akihiko Miyanaga, Sho Saito, Mizuki Yuasa, Satoshi Takahashi, Takeru Kashiwada, Teppei Sugano, Rintaro Noro, Yuji Minegishi, Yasuhiro Terasaki, Yoshinobu Saito, Kaoru Kubota, Masahiro Seike, and Akihiko Gemma.
- Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan.
- Intern. Med. 2021 Feb 15; 60 (4): 591-594.
AbstractOsimertinib is the standard treatment for epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. However, drug-induced interstitial lung disease (ILD) is recognized as a serious adverse event associated with EGFR-tyrosine kinase inhibitors (TKIs). We herein report a 78-year-old woman with stage IV lung adenocarcinoma harboring an EGFR L858R mutation on exon 21 who received rechallenge treatment with afatinib after osimertinib-induced ILD with an organizing pneumonia pattern. This is the first report of successful rechallenge with afatinib after osimertinib-induced ILD. Treatment with other EGFR-TKIs after osimertinib-induced ILD may be an option for subsequent therapy.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..